Vaccines & Disease · Ebola

Ebola (Ebola Hemorrhagic Fever)

Below are brief introductions to Ebola disease and the Ebola vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.

Published October 12, 2021
The Disease

Ebola: The Disease

Ebola is a serious contagious viral disease with a high mortality rate.1 The natural reservoir for the virus is thought to be a fruit bat native to Africa. Both humans and non-human primates are susceptible to infection.2

Symptoms start with a fever, headache, muscle and stomach pain, diarrhea, vomiting, fatigue, weakness, skin bruising and bleeding. As the disease progresses, damage to the immune system as well as the body’s internal organs occur. White blood cell and platelet counts decrease and both internal and external bleeding can occur. Fatality rates from the disease have ranged from 25 to 90 percent but the average case fatality rate is estimated at 50 percent.34 A person can have the virus but not show any symptoms for as long as three weeks.5

Persons who survive Ebola virus disease develop long-term immunity; however, health problems frequently persist upon recovery.6

The Vaccine

Ebola Vaccine

On December 19, 2019, the FDA approved ERVEBO (rVSV-ZEBOV), a genetically modified live Ebola virus vaccine for use in persons 18 years of age and older. This vaccine is manufactured by Merck and targets the Zaire ebolavirus strain.7 ERVEBO is a live, genetically modified Ebola virus vaccine and uses an attenuated vesicular stomatitis virus, a pathogen that infects livestock (cattle, horses, deer, pigs) with one of its genes replaced by an Ebolavirus gene.89

Adverse events reported during clinical trials of ERVEBO included: injection site pain, swelling, and redness; headache; fever; nausea; fatigue; muscle pain; joint pain, swelling, stiffness, warmth, and redness; abnormal sweating; rash; mouth ulcers; vesicular lesions; arthralgia; arthritis; anaphylaxis; cerebrovascular accident; hemorrhagic stroke; subarachnoid hemorrhage; pulmonary embolism; and death.10

Quick Facts

Ebola at a glance

Ebola (Ebola Hemorrhagic Fever) Quick Facts

  1. Ebola is a serious contagious disease with a high mortality rate. The incubation period from initial exposure to onset of acute disease symptoms is between 2 and 21 days with the average being 8 to 10 days. Symptoms start with a fever, headache, muscle and stomach pain, diarrhea, vomiting, and skin bruising and may also include a skin rash, red eyes, and hiccups.11 Additional symptoms may include shortness of breath, chest pain, confusion, seizures, and bleeding. White blood cell and platelet counts decrease and both internal and external bleeding can occur. Fatal cases usually present with more severe symptoms early in the course of the illness, and death generally occurs from sepsis or multiorgan failure between day 6 and 16.12
  2. The Ebola virus is transmitted through direct contact with infected blood or body fluids, or by coming into contact with objects infected by the virus. It can also be spread through exposure to infected primates (apes, monkey, etc.) or fruit bats. A person with Ebola virus is only contagious to others after they begin to show signs of illness.13

Ebola Vaccine Quick Facts

  1. On December 19, 2019, the FDA approved Merck’s ERVEBO Ebola vaccine, a genetically modified live Ebola virus vaccine for use in persons 18 years of age and older.14 The vaccine targets the species Zaire ebolavirus. The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends that ERVEBO be given to all persons responding to an outbreak of Ebola virus disease, healthcare workers treating patients at federally-designated Ebola treatment centers in the U.S., biosafety-level 4 laboratory personnel,15 healthcare personnel at specialized pathogen care centers, and to support and laboratory staff at Laboratory Response Network facilities.16
  2. The ERVEBO package insert reports that the vaccine has the potential to infect others with vaccine-strain Ebolavirus due to virus shedding.17
References
  1. 1US Centers for Disease Control and Prevention. Signs and Symptoms. May 4, 2021.
  2. 2Patel PR, Shah SU. Ebola Virus. StatPearls.
  3. 3US Centers for Disease Control and Prevention. Signs and Symptoms. May 4, 2021.
  4. 4World Health Organization. Ebola Virus Disease. Feb. 23, 2021.
  5. 5World Health Organization. Ebola Virus Disease. Feb. 23, 2021.
  6. 6US Centers for Disease Control and Prevention. Survivors. Nov. 5, 2019.
  7. 7Merck Sharp & Dohme Corp. Package Insert – ERVEBO. U.S. Food and Drug Administration. Jan. 16, 2021.
  8. 8Geisbert TW, Feldman H. Recombinant Vesicular Stomatitis Virus-Based Vaccines Against Ebola and Marburg Virus Infections. J Infect Dis Nov. 2011.
  9. 9Pauls K. Ebola Vaccine Trials Will Start in Weeks, say WHO and Company. CBC News Oct. 3, 2014.
  10. 10Merck Sharp & Dohme Corp. Approval History, Letters, Reviews, and Related Documents – ERVEBO. U.S. Food and Drug Administration Jan. 16, 2021.
  11. 11US Centers for Disease Control and Prevention. Signs and Symptoms. May 4, 2021.
  12. 12US Centers for Disease Control and Prevention. Ebola Virus Disease (EVD) Information for Clinicians in U.S. Healthcare Settings. Mar. 10, 2021.
  13. 13US Centers for Disease Control and Prevention. Transmission. Jan. 14, 2021.
  14. 14Merck Sharp & Dohme Corp. Package Insert – ERVEBO. U.S. Food and Drug Administration Jan. 16, 2021.
  15. 15Choi MJ, Cossaboom CM, Whitesell AN, et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Jan. 8, 2021; 70(1): 1–12.
  16. 16Malenfant JH, Joyce A, Choi MJ, et al. Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations — United States, 2021. MMWR Feb. 25, 2022; 71(8):290–292.
  17. 17Merck Sharp & Dohme Corp. Package Insert – ERVEBO. U.S. Food and Drug Administration Jan. 16, 2021.
Select disease / vaccine